Prolonged Use of Carnitine-Orotate Complex (Godex (R)) Is Associated with Improved Mortality: A Nationwide Cohort Study

Abstract

Despite its hepatoprotective effects and favorable metabolic effects, the association between carnitine-orotate complex (Godex (R)) intake and mortality has never been investigated. We enrolled 13,413 adults who underwent national health examination and were prescribed the carnitine-orotate complex. Subjects were classified into three groups based on duration of using carnitine-orotate complex: <30, 30-180, and >= 180 days and were followed-up until 2019. Hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality were estimated using Cox proportional hazards regression. During the follow-up period, 708 deaths were documented. Adjusted HR of mortality was 0.69 (95% CI 0.51-0.92) in those who used carnitine-orotate complex for >= 180 days compared to those who used it for <30 days. Use of carnitine-orotate complex for >= 180 days was associated with significantly reduced mortality in individuals with metabolic risk factors such as obesity, metabolic syndrome, dyslipidemia, and fatty liver than the shorter period of use. A significant interaction was observed in individuals with type 2 diabetes (HR 0.43, 95% CI 0.29-0.63, p-value 0.001). In this nationwide study, longer use of carnitine-orotate complex was associated with improved mortality compared to a shorter period of use, and the risk reductions were prominent in individuals with metabolic risk factors.